๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› B-Cell Non-Hodgkin Lymphoma
Clinical trial register · China

B-Cell Non-Hodgkin Lymphoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 6 Shanghai 6 Beijing 5 Tianjin 3 Hangzhou 2
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou6 Shanghai6 Beijing5 Tianjin3 Hangzhou2
All 18 locations
Target enrolment
to

B-Cell Non-Hodgkin Lymphoma trials in China

20 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma
NCT07661537B-cell Non-Hodgkin Lymphoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
90
Beijing, Guangzhou
2026-07-23
Not yet open
A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT07658352B-Cell Non-Hodgkin Lymphoma
Shanghai Helioson Pharmaceutical Co., Ltd.
Phase 1/2
114
Guangzhou
2026-06-26
Active, closed
Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin Lymphoma
NCT07480837B-Cell Non-Hodgkin Lymphoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
60
Beijing
2026-01-01
Recruiting
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07123454B-cell Non-Hodgkin Lymphoma
AstraZeneca
Phase 1/2
91
Chengdu, Guangzhou
2025-09-24
Not yet open
A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07068906B-Cell Non-Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
27
Tianjin
2025-07-15
Recruiting
A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )
NCT07053670B-Cell Non-Hodgkin Lymphoma
Tongji Hospital
Phase 1
27
Wuhang
2025-07-09
Not yet open
A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )
NCT07032324B-Cell Non-Hodgkin Lymphoma
Qian Wenbin
Phase 1
27
Hangzhou
2025-07-08
Not yet open
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
NCT07024147B-Cell Non-Hodgkin Lymphoma, Large B Cell Diffuse Lymphoma, Follicular Lymphoma, Marginal Zone B Cell Lymphoma
Peking University Cancer Hospital & Institute
Phase 1
20
Beijing
2025-07-01
Recruiting
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
NCT07072169B-cell Non-Hodgkin Lymphoma
Ruijin Hospital
Phase 1
56
Shanghai
2025-05-26
Recruiting
A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT06822868B-Cell Non-Hodgkin Lymphoma
Kai Hu
Phase 1
24
Beijing
2025-02-10
Recruiting
A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
NCT06734871B-Cell Non-Hodgkin Lymphoma
Aibin Liang๏ผŒMD๏ผŒPh.D.
Phase 1
24
Shanghai
2024-12-30
Recruiting
Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL
NCT06707259B-cell Non Hodgkin Lymphoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
24
Hangzhou
2024-12-01
Not yet open
ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT
NCT06646666B-cell Non Hodgkin Lymphoma
Ruijin Hospital
Phase 2
35
Shanghai
2024-12-01
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
AstraZeneca
Phase 2
270
Chengdu, Guangzhou, Nanchang, Nanjing, Nantong, Shandong, Shanghai, Tianjin
2024-11-27
Active, closed
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma
NCT06464185B-cell Non-Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
53
Tianjin
2024-04-30
Recruiting
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
NCT06365671B-cell Non Hodgkin Lymphoma
Ruijin Hospital
Phase 2
16
Shanghai
2024-04-16
Active, closed
Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma
NCT06251180B-cell Non-Hodgkin Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1
112
Guangzhou
2024-04-10
Recruiting
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
NCT05472558B-cell Non Hodgkin Lymphoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
48
Hanzhou
2022-07-26
Recruiting
A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma
NCT06725524B-cell Non Hodgkin Lymphoma
Shanghai JMT-Bio Inc.
Phase 1
186
Shanghai
2021-10-12
Rows per page Showing 1–20 of 20
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/b-cell-non-hodgkin-lymphoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 20 of those studies listing the condition B-Cell Non-Hodgkin Lymphoma.

How many B-Cell Non-Hodgkin Lymphoma trials are recruiting in China?

11 of the 20 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (B-Cell Non-Hodgkin Lymphoma), 20 studies
PhaseStudiesRecruitingShare
Phase 112860%
Phase 1/24120%
Phase 23215%
Observational105%

Most active sponsors

Lead sponsors with the most studies (B-Cell Non-Hodgkin Lymphoma)
Lead sponsorStudiesRecruiting
Ruijin Hospital32
AstraZeneca22
Institute of Hematology & Blood Diseases Hospital, China20
Second Affiliated Hospital, Zhejiang University, School of Medicine22
Aibin Liang๏ผŒMD๏ผŒPh.D.11
Cancer Institute and Hospital, Chinese Academy of Medical Sciences10
Genmab10
Guangzhou Lupeng Pharmaceutical Company LTD.10
Kai Hu11
Peking University Cancer Hospital & Institute10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.